Background/Aims: Dysregulation of integrins is a feature of tissue remodeling in autosomal-dominant polycystic kidney disease (ADPKD). The alpha 8 beta 1 integrin (α8β1) affects kidney development and the susceptibility to renal injury in mice. We investigated whether the –414 T/C polymorphism in the promoter region of the alpha 8 integrin chain gene (ITGA8) is associated with the progression of renal disease in ADPKD. Methods: Genotyping for the –414 T/C polymorphism was performed by allelic separation using RT-PCR in 294 patients with ADPKD. Alpha 8 integrin expression was detected by RT-PCR and immunohistochemistry. Results: 41% of the study population reached end stage renal disease at a mean age of 51 ± 12 years. The frequency of the –414 C allele was 0.194 in ADPKD. C allele carriers (CC and TC genotypes) were compared with patients homozygous for the T allele (TT genotype). Kaplan-Meier analysis revealed that end-stage renal failure occurred at a significantly younger age in TT homozygotes (median age, 47 years; 95% CI, 46–49 years) than in C allele carriers (median age, 51 years; 95% CI, 49–53 years; p = 0.046 by the log-rank test). When parameters of ADPKD patients were compared between genotype by analysis of variance, only age at onset of end-stage renal failure was significantly different (p = 0.026) whereas age at onset of hypertension, body surface area, 24-hour systolic and diastolic blood pressure did not differ. In kidneys of ADPKD, expression of alpha 8 integrin is increased and found de novo in cystic epithelia. Conclusion: A polymorphism of the ITGA8 promoter modifies the progression of renal failure in ADPKD.

Keywords:
Alpha 8 integrin, Promoter, Autosomal-dominant polycystic kidney disease, Association study, End-stage renal disease
1.
Giancotti FG: Complexity and specificity of integrin signalling. Nat Cell Biol 2000;2:E13–E14.
2.
Giancotti FG, Ruoslahti E: Integrin signaling. Science 1999;285:1028–1032.
3.
Kanahara K, Yorioka N, Arita M, Ohira N, Yamakido M: Immunohistochemical studies of extracellular matrix components and integrins in IgA nephropathy. Nephron 1994;66:29–37.
4.
Kuhara T, Kagami S, Kuroda Y: Expression of beta 1-integrins on activated mesangial cells in human glomerulonephritis. J Am Soc Nephrol 1997;8:1679–1687.
5.
Jin DK, Fish AJ, Wayner EA, et al: Distribution of integrin subunits in human diabetic kidneys. J Am Soc Nephrol 1996;7:2636–2645.
6.
Goligorsky MS, Lieberthal W, Racusen L, Simon EE: Integrin receptors in renal tubular epithelium: new insights into pathophysiology of acute renal failure. Am J Physiol 1993;264:F1–F8.
7.
Kagami S, Border WA, Ruoslahti E, Noble NA: Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis. Lab Invest 1993;69:68–76.
8.
Kagami S, Kondo S: Beta1-integrins and glomerular injury. J Med Invest 2004;51:1–13.
9.
Kagami S, Urushihara M, Kondo S, et al: Effects of anti-alpha1 integrin subunit antibody on anti-Thy-1 glomerulonephritis. Lab Invest 2002;82:1219–1227.
10.
Chen X, Moeckel G, Morrow JD, et al: Lack of integrin alpha1beta1 leads to severe glomerulosclerosis after glomerular injury. Am J Pathol 2004;165:617–630.
11.
Varnum-Finney B, Venstrom K, et al: The integrin receptor alpha 8 beta 1 mediates interactions of embryonic chick motor and sensory neurons with tenascin-C. Neuron 1995;14:1213–1222.
12.
Schnapp LM, Breuss JM, Ramos DM, Sheppard D, Pytela R: Sequence and tissue distribution of the human integrin alpha 8 subunit: a beta 1-associated alpha subunit expressed in smooth muscle cells. J Cell Sci 1995;108:537–544.
13.
Schnapp LM, Hatch N, Ramos DM, Klimanskaya IV, Sheppard D, Pytela R: The human integrin alpha 8 beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin. J Biol Chem 1995;270:23196–23202.
14.
Denda S, Reichardt LF, Müller U: Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol Biol Cell 1998;9:1425–1435.
15.
Brandenberger R, Schmidt A, Linton J, et al: Identification and characterization of a novel extracellular matrix protein nephronectin that is associated with integrin alpha8beta1 in the embryonic kidney. J Cell Biol 2001;154:447–458.
16.
Hartner A, Schöcklmann H, Pröls F, Müller U, Sterzel RB: Alpha8 integrin in glomerular mesangial cells and in experimental glomerulonephritis. Kidney Int 1999;56:1468–1480.
17.
Hartner A, Cordasic N, Klanke B, Müller U, Sterzel RB, Hilgers KF: The alpha8 integrin chain affords mechanical stability to the glomerular capillary tuft in hypertensive glomerular disease. Am J Pathol 2002;160:861–867.
18.
Muller U, Wang D, Denda S, Meneses JJ, Pedersen RA, Reichardt LF: Integrin alpha8 beta1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis. Cell 1997;88:603–613.
19.
Haas CS, Amann K, Schittny J, Blaser B, Muller U, Hartner A: Glomerular and renal vascular structural changes in alpha8 integrin-deficient mice. J Am Soc Nephrol 2003;14:2288–2296.
20.
Wilson PD, Burrow CR: Cystic diseases of the kidney: Role of adhesion molecules in normal and abnormal tubulogenesis. Exp Nephrol 1999;7:114–124.
21.
Daikha-Dahmane F, Narcy F, Dommergues M, Lacoste M, Beziau A, Gubler MC: Distribution of alpha-integrin subunits in fetal polycystic kidney diseases. Pediatr Nephrol 1997;11:267–273.
22.
Battini L, Fedorova E, Macip S, Li X, Wilson PD, Gusella GL: Stable knockdown of polycystin-1 confers integrin-alpha2beta1-mediated anoikis resistance. J Am Soc Nephrol 2006;17:3049–3058.
23.
Hartner A, Hilgers KF, Bitzer M, Veelken R, Schocklmann HO: Dynamic expression patterns of transforming growth factor-beta(2) and transforming growth factor-beta receptors in experimental glomerulonephritis. J Mol Med 2003;81:32–42.
24.
Riggs KJ, Merrell KT, Wilson G, Calame K: Common factor 1 is a transcriptional activator which binds in the c-myc promoter, the skeletal alpha-actin promoter, and the immunoglobulin heavy-chain enhancer. Mol Cell Biol 1991;11:1765–1769.
25.
Joly D, Morel V, Hummel A, Ruello A, Nusbaum P, Patey N, et al: Beta4 integrin and laminin 5 are aberrantly expressed in polycystic kidney disease: role in increased cell adhesion and migration. Am J Pathol 2003;163:1791–1800.
26.
Craig SW, Johnson RP: Assembly of focal adhesions: progress, paradigms, and portents. Curr Opin Cell Biol 1996;8:74–85.
27.
Lo SH, Yu QC, Degenstein L, Chen LB, Fuchs E: Progressive kidney degeneration in mice lacking tensin. J Cell Biol 1997;136:1349–1361.
28.
Klingel R, Ramadori G, Schuppan D, Knittel T, Meyer zum Buschenfelde KH, Kohler H: Coexpression of extracellular matrix glycoproteins undulin and tenascin in human autosomal dominant polycystic kidney disease. Nephron 1993;65:111–118.
29.
Daikha-Dahmane F, Dommergues M, Narcy F, Lacoste M, Gubler MC: Distribution and ontogenesis of tenascin in normal and cystic human fetal kidneys. Lab Invest 1995;73:547–557.
30.
Nadasdy T, Laszik Z, Lajoie G, Blick KE, Wheeler DE, Silva FG: Proliferative activity of cyst epithelium in human renal cystic diseases. J Am Soc Nephrol 1995;5:1462–1468.
31.
Ramasubbu K, Gretz N, Bachmann S: Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease. J Am Soc Nephrol 1998;9:937–945.
32.
Bieritz B, Spessotto P, Colombatti A, Jahn A, Prols F, Hartner A: Role of alpha8 integrin in mesangial cell adhesion, migration, and proliferation. Kidney Int 2003;64:119–127.
33.
Zargham R, Thibault G: Alpha 8 integrin expression is required for maintenance of the smooth muscle cell differentiated phenotype. Cardiovasc Res 2006;71:170–178.
34.
Avner ED, Sweeney WE Jr, Nelson WJ: Abnormal sodium pump distribution during renal tubulogenesis in congenital murine polycystic kidney disease. Proc Natl Acad Sci USA 1992;89:7447–7451.
35.
Du J, Wilson PD: Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Physiol 1995;269:C487–C495.
36.
Rocco MV, Neilson EG, Hoyer JR, Ziyadeh FN: Attenuated expression of epithelial cell adhesion molecules in murine polycystic kidney disease. Am J Physiol 1992;262:F679–F686.
37.
Levine D, Rockey DC, Milner TA, Breuss JM, Fallon JT, Schnapp LM: Expression of the integrin alpha8beta1 during pulmonary and hepatic fibrosis. Am J Pathol 2000;156:1927–1935.
38.
Bouzeghrane F, Mercure C, Reudelhuber TL, Thibault G: Alpha8beta1 integrin is upregulated in myofibroblasts of fibrotic and scarring myocardium. J Mol Cell Cardiol 2004;36:343–353.
39.
Lamnissou K, Zirogiannis P, Trygonis S, et al: Evidence for association of endothelial cell nitric oxide synthase gene polymorphism with earlier progression to end-stage renal disease in a cohort of Hellens from Greece and Cyprus. Genet Test 2004;8:319–324.
40.
Persu A, Stoenoiu MS, Messiaen T, et al: Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002;11:229–241.
41.
Ecder T, McFann KK, Raynolds MV, Schrier RW: No effect of angiotensin-converting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. Am J Nephrol 2003;23:466–470.
42.
Persu A, El-Khattabi O, Messiaen T, Pirson Y, Chauveau D, Devuyst O: Influence of ACE (I/D) and G460W polymorphism of alpha-adducin in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2003;18:2032–2038.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.